2Schuler W , Sedrani R, Cotton S, et al. SDZ RAD, a new rapamycin derivative. Transplatation, 1997, 64: 36-42.
3Benito AI, Frulong T, Martin PJ, et al. Sirolimus(rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease.Transplatation, 2001, 72: 1924-1929.
4Muthukkumar S, Ramesh T, Bondada S. Rapamycin, a potent immunosuppressive drugs, causes programmed cell death in B lymphoma cells. Transplatation, 1995, 60 : 264-270.
5Johnson R, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplatation, 2001, 72:777-786.
6Kahan BD. Potential therapeutic interventions to avoid or treat chronic allograft dysfunction. Transplatation, 2001, 71 ( Suppl ) :SS52-57.
7Dominguez J, Mahalati K, Kiberd B, et al. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplatation, 2000, 70. 1244-1247.
8Fishbein TM, Florman S, Gondolesi G. Intestinal transplantation before and after the introduction of sirolimus. Transplantation,2002, 73: 1538.
9Hong JC, Kahan BD. Sirolimus rescue therapy for refractory rejection in renal transplantation. Transplatation, 2001, 71 : 1579-1584.
10Sindhi R, Webber S, Venkataramanan R, et al, Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus, Transplatation, 2001, 72: 851-855.
